Skip to main content
Top
Published in: Malaria Journal 1/2014

Open Access 01-12-2014 | Case study

The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso

Authors: Halidou Tinto, Innocent Valea, Hermann Sorgho, Marc Christian Tahita, Maminata Traore, Biébo Bihoun, Issa Guiraud, Hervé Kpoda, Jérémi Rouamba, Sayouba Ouédraogo, Palpouguini Lompo, Sandrine Yara, William Kabore, Jean-Bosco Ouédraogo, Robert Tinga Guiguemdé, Fred N Binka, Bernhards Ogutu

Published in: Malaria Journal | Issue 1/2014

Login to get access

Abstract

Background

The opportunities for developing new drugs and vaccines for malaria control look brighter now than ten years ago. However, there are few places in sub-Saharan Africa with the necessary infrastructure and expertise to support such research in compliance to international standards of clinical research (ICH-GCP). The Clinical Research Unit of Nanoro (CRUN) was founded in 2008 to provide a much-needed GCP-compliant clinical trial platform for an imminent large-scale Phase 3 malaria vaccine trial. A dynamic approach was used that entailed developing the required infrastructure and human resources, while engaging local communities in the process as key stakeholders. This provided a better understanding and ownership of the research activities by the local population.

Case description

Within five years (2008–2013), the CRUN set up a fully and well-equipped GCP-compliant clinical trial research facility, which enabled to attract 25 grants. The research team grew from ten health workers prior to 2008 to 254 in 2013. A Health and Demographic Surveillance System (HDSS), which covers a total population of about 60,000 people in 24 villages was set up in the district. The local community contributed to the development of the facility through the leadership of the king and the mayor of Nanoro. As a result of their active advocacy, the government extended the national electrical grid to the new research center, and later to the entire village. This produced a positive impact on the community’s quality of life. The quality of health care improved substantially, due to the creation of more elaborate clinical laboratory services and the acquisition of state-of-the-art equipment.

Conclusion

Involving the community in the key steps of establishing the centre provided the foundation for what was to become the CRUN success story. This experience demonstrates that when clinical trials research sites are carefully developed and implemented, they can have a positive and powerful impact on local communities in resource-poor settings, well beyond the task of generating expected study data.
Appendix
Available only for authorised users
Literature
1.
go back to reference WHO: World Malaria Report 2011. 2011, Geneva: WHO WHO: World Malaria Report 2011. 2011, Geneva: WHO
2.
go back to reference Lang TA, Kokwaro GO: Malaria drug and vaccine trials in Africa: obstacles and opportunities. Trans R Soc Trop Med Hyg. 2008, 102: 7-10. 10.1016/j.trstmh.2007.08.008.CrossRefPubMed Lang TA, Kokwaro GO: Malaria drug and vaccine trials in Africa: obstacles and opportunities. Trans R Soc Trop Med Hyg. 2008, 102: 7-10. 10.1016/j.trstmh.2007.08.008.CrossRefPubMed
3.
go back to reference Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer WH: From malaria control to eradication: the WHO perspective. Trop Med Int Health. 2009, 14: 802-809. 10.1111/j.1365-3156.2009.02287.x.CrossRefPubMed Mendis K, Rietveld A, Warsame M, Bosman A, Greenwood B, Wernsdorfer WH: From malaria control to eradication: the WHO perspective. Trop Med Int Health. 2009, 14: 802-809. 10.1111/j.1365-3156.2009.02287.x.CrossRefPubMed
4.
go back to reference Kouyaté B, Sie A, Yé M, De Allegri M, Müller O: The great failure of malaria control in africa: a district perspective from Burkina Faso. PLoS Med. 2007, 4: 4-CrossRef Kouyaté B, Sie A, Yé M, De Allegri M, Müller O: The great failure of malaria control in africa: a district perspective from Burkina Faso. PLoS Med. 2007, 4: 4-CrossRef
5.
go back to reference Ogutu BR, Baiden R, Diallo D, Smith PG, Binka FN: Sustainable development of a GCP-compliant clinical trials platform in Africa: the malaria clinical trials alliance perspective. Malar J. 2010, 9: 103-10.1186/1475-2875-9-103.PubMedCentralCrossRefPubMed Ogutu BR, Baiden R, Diallo D, Smith PG, Binka FN: Sustainable development of a GCP-compliant clinical trials platform in Africa: the malaria clinical trials alliance perspective. Malar J. 2010, 9: 103-10.1186/1475-2875-9-103.PubMedCentralCrossRefPubMed
6.
go back to reference Gbary AR, Guiguemde TR, Ouedraogo JB, Baudon D, Douchet CJ, Le Bras J, Breman J: The OCCGE (Organisation de Coordination et de Coopération pour la Lutte contre les Grandes Endémies) and the surveillance of the drug sensitivity of Plasmodium falciparum to antimalarials. Bull Soc Pathol Exot Filiales. 1987, 80 (3 Pt 2): 461-468.PubMed Gbary AR, Guiguemde TR, Ouedraogo JB, Baudon D, Douchet CJ, Le Bras J, Breman J: The OCCGE (Organisation de Coordination et de Coopération pour la Lutte contre les Grandes Endémies) and the surveillance of the drug sensitivity of Plasmodium falciparum to antimalarials. Bull Soc Pathol Exot Filiales. 1987, 80 (3 Pt 2): 461-468.PubMed
7.
go back to reference Nabarro DN, Tayler EM: The “roll back malaria” campaign. Science. 2067–2068, 1998: 280- Nabarro DN, Tayler EM: The “roll back malaria” campaign. Science. 2067–2068, 1998: 280-
8.
go back to reference Gansané A, Nébié I, Soulama I, Tiono A, Diarra A, Konaté AT, Ouédraogo A, Sirima BS: Change of antimalarial first-line treatment in Burkina Faso in 2005. Bull la Soc Pathol Exot 1990. 2009, 102: 31-35.CrossRef Gansané A, Nébié I, Soulama I, Tiono A, Diarra A, Konaté AT, Ouédraogo A, Sirima BS: Change of antimalarial first-line treatment in Burkina Faso in 2005. Bull la Soc Pathol Exot 1990. 2009, 102: 31-35.CrossRef
9.
go back to reference Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D’Alessandro U: Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009, 4: e7871-10.1371/journal.pone.0007871.PubMedCentralCrossRefPubMed Bassat Q, Mulenga M, Tinto H, Piola P, Borrmann S, Menéndez C, Nambozi M, Valéa I, Nabasumba C, Sasi P, Bacchieri A, Corsi M, Ubben D, Talisuna A, D’Alessandro U: Dihydroartemisinin-piperaquine and artemether-lumefantrine for treating uncomplicated malaria in African children: a randomised, non-inferiority trial. PLoS One. 2009, 4: e7871-10.1371/journal.pone.0007871.PubMedCentralCrossRefPubMed
10.
go back to reference Group FA-BC (4ABC) S: A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011, 8: e1001119-10.1371/journal.pmed.1001119.CrossRef Group FA-BC (4ABC) S: A head-to-head comparison of four artemisinin-based combinations for treating uncomplicated malaria in African children: a randomized trial. PLoS Med. 2011, 8: e1001119-10.1371/journal.pmed.1001119.CrossRef
11.
go back to reference Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BGNO, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R: First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med. 2011, 365: 1863-1875.CrossRefPubMed Agnandji ST, Lell B, Soulanoudjingar SS, Fernandes JF, Abossolo BP, Conzelmann C, Methogo BGNO, Doucka Y, Flamen A, Mordmüller B, Issifou S, Kremsner PG, Sacarlal J, Aide P, Lanaspa M, Aponte JJ, Nhamuave A, Quelhas D, Bassat Q, Mandjate S, Macete E, Alonso P, Abdulla S, Salim N, Juma O, Shomari M, Shubis K, Machera F, Hamad AS, Minja R: First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med. 2011, 365: 1863-1875.CrossRefPubMed
12.
go back to reference Derra K, Rouamba E, Kazienga A, Ouedraogo S, Tahita MC, Sorgho H, Valea I, Tinto H: Profile: Nanoro health and demographic surveillance system. Int J Epidemiol. 2012, 41: 1293-1301. 10.1093/ije/dys159.CrossRefPubMed Derra K, Rouamba E, Kazienga A, Ouedraogo S, Tahita MC, Sorgho H, Valea I, Tinto H: Profile: Nanoro health and demographic surveillance system. Int J Epidemiol. 2012, 41: 1293-1301. 10.1093/ije/dys159.CrossRefPubMed
13.
go back to reference Tinto H, Noor RA, Wanga CL, Valea I, Mbaye MN, D’Alessandro URR: Good clinical practice in resource-limited settings: translating theory into practice. Am J Trop Med Hyg. 2013, 88: 608-613. 10.4269/ajtmh.12-0330.PubMedCentralCrossRefPubMed Tinto H, Noor RA, Wanga CL, Valea I, Mbaye MN, D’Alessandro URR: Good clinical practice in resource-limited settings: translating theory into practice. Am J Trop Med Hyg. 2013, 88: 608-613. 10.4269/ajtmh.12-0330.PubMedCentralCrossRefPubMed
14.
go back to reference Engelking C: Clinical trials: impact evaluation and implementation considerations. Semin Oncol Nurs. 1992, 8: 148-155. 10.1016/0749-2081(92)90030-7.CrossRefPubMed Engelking C: Clinical trials: impact evaluation and implementation considerations. Semin Oncol Nurs. 1992, 8: 148-155. 10.1016/0749-2081(92)90030-7.CrossRefPubMed
15.
go back to reference Probstfield JL, Russell ML, Silvers A, Goodwin DL, Insull W: Impact of randomized clinical trials on medical practices. Control Clin Trials. 1984, 10 (4 Suppl): 321-327.CrossRef Probstfield JL, Russell ML, Silvers A, Goodwin DL, Insull W: Impact of randomized clinical trials on medical practices. Control Clin Trials. 1984, 10 (4 Suppl): 321-327.CrossRef
16.
go back to reference Ogechi E, Ragi A, Mwangi J: Strengthening linkages between Kenyan communities and AIDS vaccine trial sites. XVII Int AIDS Conf 3–8 August 2008, Mex City. 2008, Mexico Ogechi E, Ragi A, Mwangi J: Strengthening linkages between Kenyan communities and AIDS vaccine trial sites. XVII Int AIDS Conf 3–8 August 2008, Mex City. 2008, Mexico
17.
go back to reference Fitchett JR: Ethical considerations of clinical trials in the developing world. Trans R Soc Trop Med Hyg. 2009, 103: 756-760. 10.1016/j.trstmh.2009.02.021.CrossRefPubMed Fitchett JR: Ethical considerations of clinical trials in the developing world. Trans R Soc Trop Med Hyg. 2009, 103: 756-760. 10.1016/j.trstmh.2009.02.021.CrossRefPubMed
Metadata
Title
The impact of clinical research activities on communities in rural Africa: the development of the Clinical Research Unit of Nanoro (CRUN) in Burkina Faso
Authors
Halidou Tinto
Innocent Valea
Hermann Sorgho
Marc Christian Tahita
Maminata Traore
Biébo Bihoun
Issa Guiraud
Hervé Kpoda
Jérémi Rouamba
Sayouba Ouédraogo
Palpouguini Lompo
Sandrine Yara
William Kabore
Jean-Bosco Ouédraogo
Robert Tinga Guiguemdé
Fred N Binka
Bernhards Ogutu
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2014
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/1475-2875-13-113

Other articles of this Issue 1/2014

Malaria Journal 1/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.